Published on 18/11/2025

Investigator’s Brochure (IB) Authoring & Updates in Practice: Step-by-Step Guide for Sponsors, CROs and Sites

The Investigator’s Brochure (IB) is a critical document in the realm of clinical trial research. It functions as a comprehensive resource for investigators, providing essential information about the study drug or device, its properties, and the clinical trial procedures involved. This guide serves to outline the step-by-step process of authoring and updating an IB, ensuring compliance with regulatory requirements and maintaining the highest standards of Good Clinical Practice (GCP). The target audience for this guide includes professionals in clinical operations, regulatory affairs, and medical affairs across the US, UK, and EU.

Understanding the Investigator’s Brochure

The Investigator’s Brochure is not just an annotation of the product but serves various purposes in the clinical trial process:

• Summary of Clinical Information: The IB provides a summarised overview of the investigational medicinal product (IMP), including its chemical structure, pharmacological effects, and prior clinical data.
• Guidance for Investigators: It serves as a detailed guide for investigators, containing critical information on study methods, risks, and protocols that must be adhered to during the trial.
• Regulatory Compliance: The IB must comply with legal requirements set forth by regulatory authorities such as FDA, EMA, and MHRA, particularly in terms of the data it presents.

Understanding these elements is vital when embarking on the authoring or updating of an IB, as they guide the compilation of accurate information which plays a significant role in the success of any clinical trial.

Step 1: Preparing for the IB Development

Before initiating the drafting process, it is crucial to prepare adequately:

• Assemble a Core Team: Bring together a team of experts from various fields such as clinical operations, regulatory affairs, and pharmacovigilance. This cross-functional collaboration ensures an all-encompassing view of the data that will be included.
• Gather Previous IBs and Relevant Documents: Review existing IBs along with safety reports, previous clinical study reports, and regulatory feedback to ensure that all necessary information is captured and carried forward.
• Define the Target Audience: It is vital to identify the primary readers of the IB. This typically includes investigators and ethics committees, but understanding their needs helps to tailor the document appropriately.

Preparing adequately in this stage sets the foundation for the subsequent steps in the authoring process.

Step 2: Conducting a Literature Review

The next step is conducting a thorough literature review to gather current data on the investigational product:

• Search for Previous Studies: Utilize clinical trial databases to locate existing studies related to the product. This may include the trial search clinical trials database where numerous studies can be referenced.
• Evaluate Scientific Publications: Analyze published peer-reviewed articles to gather insights on prior safety and efficacy data of the investigational medicinal product.
• Review findings from Related Trials: Understand outcomes from similar products or therapies, such as those seen in the tropics 02 clinical trial, that can inform your descriptions and rationale in the IB.

The information collected during this stage is instrumental in ensuring that the IB is comprehensive and reflective of the current knowledge landscape.

Step 3: Structuring the IB

With preliminary data in hand, your next step is structuring the Investigator’s Brochure. A typical IB should be organized as follows:

• Cover Page: Title, version, and date of the IB.
• Table of Contents: Organized wayfinding for the readers.
• Product Information: Detailed description of the drug, including its pharmacology, chemistry, and mechanism of action.
• Non-clinical Studies: Results of preclinical studies that illustrate the safety and rationale for human use.
• Clinical Studies: Information from completed and ongoing clinical trials, including safety and efficacy data.
• Subject Information: Adverse reactions and risk assessments that provide investigators with a comprehensive understanding of patient safety.
• Regulatory Information: Details on compliance with regulations from agencies like FDA and EMA, highlighting any deviations or warnings.

Ensuring that information is presented logically and accessibly guarantees that investigators can easily understand the comprehensive data in the IB.

Step 4: Writing the IB

With the structure defined, one can begin the actual writing process of the IB:

• Conciseness and Clarity: Strive for clear and concise writing to ensure the document is understandable. Avoid jargon unless necessary and provide definitions where applicable.
• Incorporate Evidence-Based Data: Support all claims with references to data gathered during the literature review, including clinical trial results such as those from the olympia clinical trial.
• Collaborate on Drafts: Utilize a collaborative platform where all stakeholders can contribute, review, and provide insights on their area of expertise.

Writing the IB is an iterative process, and feedback is essential in refining the document further.

Step 5: Reviewing and Updating the IB

Once the initial draft is complete, the review process begins:

• Internal Review: Conduct an internal review among team members, focusing on clarity, data accuracy, and regulatory compliance.
• External Validation: Seek input from independent experts who can provide insights on both the content and the presentation of the IB.
• Plan for Regular Updates: The IB must be a living document that is regularly updated as new information becomes available, especially when new data from ongoing studies emerges.

The focus during this phase should be on achieving a document that is both comprehensive and precise.

Step 6: Distribution and Regulatory Submission

With a finalized IB ready, the next step is its distribution and regulatory submission:

• Distribute to Investigators: Ensure that all investigators and their team members have access to the final document prior to trial initiation.
• Submit to Regulatory Authorities: Depending on geographical regulations, submit the IB as part of the clinical trial application (CTA) process to regulatory bodies like FDA or Health Canada.
• Documentation of Changes: Keep track of version changes rigorously; an audit trail must be maintained to account for updates and revisions made pre-and post-trial initiation.

This stage not only assures the integrity of the review process but also maintains transparency with regulatory authorities.

Conclusion

The investigator’s brochure serves a fundamental role in the efficient conduct of any clinical trial, encompassing everything from the initial authoring to subsequent updates. By following the structured approach outlined in this guide, sponsors, Contract Research Organizations (CROs), and clinical sites can ensure their IBs meet regulatory standards while effectively conveying vital information to clinical trial investigators. This systematic method not only improves the accuracy and reliability of the IB but also fosters collaboration and compliance throughout the entire clinical trial process.